Cempra Pharmaceuticals, Inc. Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results From Patients With Community Acquired Bacterial Pneumonia (CABP)
5/20/2013 10:43:08 AM
More...
|
Cempra Pharmaceuticals, Inc., Toyama Chemical Company Ink Up to $70 Million Pact to Produce Anti-Pneumonia Drug
5/14/2013 6:39:32 AM
More...
|
Cempra Pharmaceuticals, Inc. to Present Data on Solithromycin's (CEM-101) Potential Against Urogenital Infections and Multidrug-Resistant Pathogens at ECCMID
4/29/2013 9:30:40 AM
More...
|
Cempra Pharmaceuticals, Inc. Reports First Quarter 2013 Financial and Operating Results
4/26/2013 7:42:27 AM
More...
|
Cempra Pharmaceuticals, Inc. to Present at 12th Annual Needham Healthcare Conference
4/25/2013 6:46:54 AM
More...
|
Cempra Pharmaceuticals, Inc. to Report First Quarter 2013 Financial and Operating Results, and Host Conference Call and Webcast on April 25, 2013
4/19/2013 7:10:11 AM
More...
|
Cempra Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2012 Financial and Operating Results
3/1/2013 7:33:54 AM
More...
|
Cempra Pharmaceuticals, Inc. to Present at Cowen and Company 33rd Annual Health Care Conference
2/27/2013 6:58:16 AM
More...
|
Cempra Pharmaceuticals, Inc. to Report Fourth Quarter and Full Year 2012 Financial and Operating Results, and Host Conference Call and Webcast on February 28, 2013
2/22/2013 7:20:35 AM
More...
|
Grant Awarded to Study Novel Therapies for Muco-Obstructive Diseases Includes Studies on Cempra Pharmaceuticals, Inc.'s Solithromycin (CEM-101) in a Cystic Fibrosis Anti-inflammatory Model
2/12/2013 9:14:25 AM
More...
|
|